Compare PLNT & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLNT | NAMS |
|---|---|---|
| Founded | 1992 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.1B |
| IPO Year | 2015 | N/A |
| Metric | PLNT | NAMS |
|---|---|---|
| Price | $53.31 | $34.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | ★ $107.46 | $46.75 |
| AVG Volume (30 Days) | ★ 1.8M | 1.1M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,324,144,000.00 | N/A |
| Revenue This Year | $19.22 | $17.96 |
| Revenue Next Year | $11.66 | $540.65 |
| P/E Ratio | $38.47 | ★ N/A |
| Revenue Growth | ★ 12.06 | N/A |
| 52 Week Low | $37.03 | $20.53 |
| 52 Week High | $114.47 | $42.21 |
| Indicator | PLNT | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 52.14 | 61.14 |
| Support Level | $49.36 | $33.83 |
| Resistance Level | $54.47 | $37.27 |
| Average True Range (ATR) | 1.75 | 1.53 |
| MACD | 0.53 | 0.57 |
| Stochastic Oscillator | 80.16 | 79.16 |
Planet Fitness Inc is a franchisor and operator of fitness centers in the United States. The company's reportable segments are Franchise, Corporate-owned stores, and Equipment. Franchise segment includes operations related to its franchising business in the United States, Puerto Rico, Canada, Panama, Mexico and Australia, Corporate-owned stores segment includes operations with respect to all corporate-owned stores throughout the United States and Canada, and The Equipment segment includes the sale of equipment to franchisee-owned stores in the U.S. The firm generates a majority of its revenue from the Corporate-owned stores segment.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.